In the subcutaneous xenograft tumor model, the positive rates (percentage expression) of LYVE-1, VEGF-C and VEGFR-3 in the control group were 47.28 ± 1.17%, 41.84 ± 0.83%, and 50.18 ± 1.71%, respectively, and those in the PZH group were 28.37 ± 1.67%, 18.39 ± 1.11%, and 26.71 ± 0.62%, respectively. This evidence concerns the gene LYVE1 and neoplasm.